Argentina is in the process of developing its vaccine against the coronavirus, called Corovax G3.
At this time, tests are being carried out on rodents and the first results can be considered successful. This has left the scientists in charge optimistic about the potential of this drug for the future.
Part of the initial results show that the animals’ immunity has not waned for five months.
At the same time, scientists think that people would only need one dose of these vaccines to fight COVID-19.
“It is a very powerful vaccine, it develops neutralizing antibodies,” says Sabrina Vinzón, a researcher at the National Council for Scientific and Technical Research (CONICET).
The professional also highlights the “prolonged cellular immune response” caused by the vaccine and that could be extended to all the variants discovered.
“It would not only protect against the original strain of the coronavirus, which began to circulate in early 2020. We show that it can protect against new strains, and those currently prevalent in our region,” he adds.
On this point, a publication in the journal Vaccines confirms that the vaccine is capable of neutralizing the Delta, Alpha and Gamma variants.
Now, the researchers plan to do clinical evaluations in humans, which could be carried out between the end of this year and the beginning of 2022.
“It is a national development, for us it is very important. We are Argentine scientists, the idea is to help us and also the rest of the countries ”, comment the CONICET researchers.